PGEN SEC Filing News — Precigen, Inc.

Latest SEC filings for Precigen, Inc. (PGEN) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-24.

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell t…
Sector: Healthcare Industry: Biotechnology Market Cap: $2.4B
20
Total Filings
1
Bullish Classifications
6
Bearish Classifications
11
Insider Transactions
1
Material Events (8-K)
1
Periodic Reports
Rule-based classifications for PGEN currently lean bearish. Of the 20 filing records displayed, 6 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 1 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
PGEN Filing Activity Snapshot 2026-07-31 — 2026-09-24
Insider Transactions (Form 4)
1 buy vs 6 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$1.38M
KINDLER JEFFREY B (Director) · 2026-08-28
185,000 shares · Form 4
Form 144 Notices
7
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 11 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 11 filings in this group are Form 4s for Precigen, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 11 insider filings shown, the breakdown is 6 open-market sale, 4 option exercise and 1 open-market purchase. 7 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×6
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Option exercise ×4
The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.
Open-market purchase ×1
The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.
Form 4 Option exercise Tax / Compensation Filing 2026-09-24

PGEN insider Form 4 filed for equity award, exercise, or tax withholding

Thomasian Harry Jr. (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 10,744 $4.72 $50.7K
M Option exercise 42,918 $2.33 $100.0K
M Option exercise 2 $0.96 $1.92
M Option exercise 1 $1.21 $1.21
M Option exercise derivative · Option to Purchase Common Stock (Right to Buy) 10,744 — —
M Option exercise derivative · Option to Purchase Common Stock (Right to Buy) 42,918 — —
M Option exercise derivative · Option to Purchase Common Stock (Right to Buy) 2 — —
M Option exercise derivative · Option to Purchase Common Stock (Right to Buy) 1 — —
Filing: Form 4 (Insider Transaction) Insider: Thomasian Harry Jr. (Chief Financial Officer) Shares: 53,665
Form 4 Open-market sale Insider Selling 2026-08-28

PGEN insider KINDLER JEFFREY B (Director) sold 185,000 shares (~$1.38M)

KINDLER JEFFREY B, listed as Director at PRECIGEN, INC., reported an open-market sale of 185,000 PGEN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 185,000 $7.44 $1.38M
Filing: Form 4 (Insider Transaction) Insider: KINDLER JEFFREY B (Director) Shares: 185,000 Est. Value: $1.38M
Form 4 Open-market purchase Insider Buying 2026-08-25

PGEN insider AGEE NANCY H (Director) bought 3,411 shares (~$24.7K)

AGEE NANCY H, listed as Director at PRECIGEN, INC., reported an open-market purchase of 3,411 PGEN shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code Nature Shares Price Value
P Open-market purchase 3,411 $7.23 $24.7K
Filing: Form 4 (Insider Transaction) Insider: AGEE NANCY H (Director) Shares: 3,411 Est. Value: $24.7K
Form 4 Option exercise Tax / Compensation Filing 2026-08-25

PGEN insider Form 4 filed for equity award, exercise, or tax withholding

Lehr Donald P. (Chief Legal Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 5,208 — —
F Tax withholding on vested shares 2,488 $7.20 $17.9K
M Option exercise derivative · Restricted Stock Units 5,208 — —
Filing: Form 4 (Insider Transaction) Insider: Lehr Donald P. (Chief Legal Officer) Shares: 7,696
Form 4 Option exercise Tax / Compensation Filing 2026-08-25

PGEN insider Form 4 filed for equity award, exercise, or tax withholding

Thomasian Harry Jr. (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 7,291 — —
F Tax withholding on vested shares 3,577 $7.20 $25.8K
M Option exercise derivative · Restricted Stock Units 7,291 — —
Filing: Form 4 (Insider Transaction) Insider: Thomasian Harry Jr. (Chief Financial Officer) Shares: 10,868
Form 4 Open-market sale Insider Selling 2026-08-25

PGEN insider Shah Rutul R (Chief Operating Officer) sold 50,000 shares (~$375.0K)

Shah Rutul R, listed as Chief Operating Officer at PRECIGEN, INC., reported an open-market sale of 50,000 PGEN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 34,658 $2.33 $80.8K
S Open-market sale 34,658 $7.50 $259.9K
M Option exercise 7,500 — —
F Tax withholding on vested shares 3,647 $7.20 $26.3K
M Option exercise 15,342 $2.33 $35.7K
S Open-market sale 15,342 $7.50 $115.1K
M Option exercise derivative · Option to Purchase Common Stock (Right to Buy) 34,658 — —
M Option exercise derivative · Restricted Stock Units 7,500 — —
M Option exercise derivative · Option to Purchase Common Stock (Right to Buy) 15,342 — —
Filing: Form 4 (Insider Transaction) Insider: Shah Rutul R (Chief Operating Officer) Shares: 50,000 Est. Value: $375.0K
Form 4 Open-market sale Insider Selling 2026-08-25

PGEN insider Tennant Phil (Chief Commercial Officer) sold 79,166 shares (~$593.7K)

Tennant Phil, listed as Chief Commercial Officer at PRECIGEN, INC., reported an open-market sale of 79,166 PGEN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 5,208 — —
F Tax withholding on vested shares 2,585 $7.20 $18.6K
M Option exercise 79,166 $1.61 $127.5K
S Open-market sale 79,166 $7.50 $593.7K
M Option exercise derivative · Restricted Stock Units 5,208 — —
M Option exercise derivative · Option to Purchase Common Stock (Right to Buy) 79,166 — —
Filing: Form 4 (Insider Transaction) Insider: Tennant Phil (Chief Commercial Officer) Shares: 79,166 Est. Value: $593.7K
Form 4 Option exercise Tax / Compensation Filing 2026-08-25

PGEN insider Form 4 filed for equity award, exercise, or tax withholding

Sabzevari Helen (President and CEO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 20,833 — —
F Tax withholding on vested shares 10,184 $7.20 $73.3K
M Option exercise derivative · Restricted Stock Units 20,833 — —
Filing: Form 4 (Insider Transaction) Insider: Sabzevari Helen (President and CEO) Shares: 31,017
Form 4 Open-market sale Insider Selling 2026-08-07

PGEN insider Shah Rutul R (Chief Operating Officer) sold 32,739 shares (~$224.6K)

Shah Rutul R, listed as Chief Operating Officer at PRECIGEN, INC., reported an open-market sale of 32,739 PGEN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 32,739 $6.86 $224.6K
Filing: Form 4 (Insider Transaction) Insider: Shah Rutul R (Chief Operating Officer) Shares: 32,739 Est. Value: $224.6K
Form 4 Open-market sale Insider Selling 2026-08-03

PGEN insider Shah Rutul R (Chief Operating Officer) sold 33,772 shares (~$219.5K)

Shah Rutul R, listed as Chief Operating Officer at PRECIGEN, INC., reported an open-market sale of 33,772 PGEN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 33,772 $2.33 $78.7K
S Open-market sale 33,772 $6.50 $219.5K
M Option exercise derivative · Option to Purchase Common Stock (Right to Buy) 33,772 — —
Filing: Form 4 (Insider Transaction) Insider: Shah Rutul R (Chief Operating Officer) Shares: 33,772 Est. Value: $219.5K
Form 4 Open-market sale Insider Selling 2026-07-31

PGEN insider Thomasian Harry Jr. (Chief Financial Officer) sold 100,000 shares (~$606.0K)

Thomasian Harry Jr., listed as Chief Financial Officer at PRECIGEN, INC., reported an open-market sale of 100,000 PGEN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 100,000 $6.06 $606.0K
Filing: Form 4 (Insider Transaction) Insider: Thomasian Harry Jr. (Chief Financial Officer) Shares: 100,000 Est. Value: $606.0K
Proposed Insider Sales 7 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Precigen, Inc. has 7 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-08-26

PGEN Form 144 filed for proposed insider sale by Jeffrey Kindler (185,000 shares) ~$1.37M

Jeffrey Kindler filed a Form 144 with the SEC indicating intent to sell PGEN (PRECIGEN, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Jeffrey Kindler Shares: 185,000 Est. Value: $1.37M
Form 144 Proposed Insider Sale 2026-08-25

PGEN Form 144 filed for proposed insider sale by Shah Rutul R (15,342 shares) ~$115.1K

Shah Rutul R filed a Form 144 with the SEC indicating intent to sell PGEN (PRECIGEN, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Shah Rutul R Shares: 15,342 Est. Value: $115.1K
Form 144 Proposed Insider Sale 2026-08-25

PGEN Form 144 filed for proposed insider sale by Tennant Phil (79,166 shares) ~$593.7K

Tennant Phil filed a Form 144 with the SEC indicating intent to sell PGEN (PRECIGEN, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Tennant Phil Shares: 79,166 Est. Value: $593.7K
Form 144 Proposed Insider Sale 2026-08-21

PGEN Form 144 filed for proposed insider sale by Shah Rutul R (34,658 shares) ~$259.9K

Shah Rutul R filed a Form 144 with the SEC indicating intent to sell PGEN (PRECIGEN, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Shah Rutul R Shares: 34,658 Est. Value: $259.9K
Form 144 Proposed Insider Sale 2026-08-06

PGEN Form 144 filed for proposed insider sale by Shah Rutul R (32,739 shares) ~$224.6K

Shah Rutul R filed a Form 144 with the SEC indicating intent to sell PGEN (PRECIGEN, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Shah Rutul R Shares: 32,739 Est. Value: $224.6K
Form 144 Proposed Insider Sale 2026-08-03

PGEN Form 144 filed for proposed insider sale by Shah Rutul R (33,772 shares) ~$219.5K

Shah Rutul R filed a Form 144 with the SEC indicating intent to sell PGEN (PRECIGEN, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Shah Rutul R Shares: 33,772 Est. Value: $219.5K
Form 144 Proposed Insider Sale 2026-07-31

PGEN Form 144 filed for proposed insider sale by Thomasian Harry Jr. (100,000 shares) ~$605.6K

Thomasian Harry Jr. filed a Form 144 with the SEC indicating intent to sell PGEN (PRECIGEN, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Thomasian Harry Jr. Shares: 100,000 Est. Value: $605.6K
Material Events 1 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There is 1 in this period for Precigen, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-04

PGEN filed 8-K — material company event

PRECIGEN, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Precigen, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-04

PGEN filed Quarterly Report (10-Q)

PRECIGEN, INC. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

How we classify Precigen, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on PGEN. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — PGEN SEC Filings

More Tools for PGEN

Want deeper PGEN analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the PGEN stock analysis page.

PGEN Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer